Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Xuanwu Hospital, Beijing
Assistance Publique - Hôpitaux de Paris
Beijing Bio-Targeting Therapeutics Technology Co., Ltd
Huashan Hospital
Azienda Sanitaria dell'Alto Adige
University of Alabama at Birmingham
Coherence Neuro Australia Pty Limited
Washington University School of Medicine
Tetragon Biosciences Ltd
Washington University School of Medicine
Washington University School of Medicine
NYU Langone Health
Yale University
Baptist Health South Florida
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
NRG Oncology
Trogenix ltd
Maastricht University Medical Center
Tianjin Medical University Cancer Institute and Hospital
Ipsen
Weill Medical College of Cornell University
Vanderbilt-Ingram Cancer Center
Case Comprehensive Cancer Center
The Cooper Health System
Assistance Publique - Hôpitaux de Paris
Cancer Research UK
M.D. Anderson Cancer Center
Exelixis
Lantern Pharma Inc.
Hospices Civils de Lyon
University of Alabama at Birmingham
Duke University
Northwestern University
Clinica Universidad de Navarra, Universidad de Navarra
Jonsson Comprehensive Cancer Center
King's College Hospital NHS Trust
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Insel Gruppe AG, University Hospital Bern
VA Office of Research and Development
OHSU Knight Cancer Institute
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
University of Alabama at Birmingham
University Hospital, Montpellier
Baylor College of Medicine
University of Texas Southwestern Medical Center
Washington University School of Medicine
Dana-Farber Cancer Institute